Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Vitamin B2/migraine study

This article was originally published in The Tan Sheet

Executive Summary

Vitamin B2/migraine study: Riboflavin (vitamin B2) "is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug," J. Schoenen, MD, University of Liege, Belgium, et al., conclude in a three-month, 55-subject study published in the February issue of Neurology. Riboflavin at the 400 mg dosage tested "was superior to placebo in reducing attack frequency and headache days," the study says. Three "minor" adverse events occurred -- two (diarrhea and polyuria) in the riboflavin group and one (abdominal cramps) among those on placebo, Schoenen et al. note...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel